Please login to the form below

BACE inhibitor

This page shows the latest BACE inhibitor news and features for those working in and with pharma, biotech and healthcare.

Eisai to tackle dementia in new US research facility

Merck &Co has also seen failure with its BACE1 inhibitor verubecestat, which also led to the drug’s abandonment. ... However Eisai, which also has a BACE inhibitor elenbecestat in late-stage testing, has several dementia candidates in its pipeline, and

Latest news

Daily Brief: PRIME status for vaccine, NHS urged to adopt automation, Brexit vote loom

Today’s biggest pharma news is more grim tidings from the field of Alzheimer’s research – AZ and Lilly have conceded defeat on their BACE inhibitor. ... Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat.
Daily Brief: PRIME status for vaccine, NHS urged to adopt automation, Brexit votes loom

Today’s biggest pharma news is more grim tidings from the field of Alzheimer’s research – AZ and Lilly have conceded defeat on their BACE inhibitor. ... Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat.
Merck BACE inhibitor adds to litany of Alzheimer's trial failures

Merck BACE inhibitor adds to litany of Alzheimer's trial failures. Interim data shows “ virtually no chance” of clinical success for verubecestat. ... The latest disappointment comes from a phase II/III study of Merck &Co's BACE inhibitor verubecestat
Biogen rises on more positive data for Alzheimer's candidate

compounds. Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
Lilly taps AstraZeneca for another anti-amyloid drug

The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running ... secretase inhibitor semagacestat.

More from news
Approximately 2 fully matching, plus 25 partially matching documents found.

Latest Intelligence

Deal Watch table for September 2014

Licence and collaboration. Oral BACE inhibitor in phase I for Alzheimer's disease. ... TGR-1202 an oral P13K-delta inhibitor in phase II for haematological malignancies.
Pharma deals during September 2014

The product, an oral PK13 delta inhibitor appears to have completed phase 2 the stage when most options would expire. ... AstraZeneca and Lilly have announced a joint development and commercialisation deal for AstraZeneca's BACE inhibitor in phase I for
Eisai: Bucking the trend with R&D growth

BACE inhibitor E2609.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Graduate Scientific Editor: DOE

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Associate Scientific Director: Salary TBC

Market Access Consultant - Greater Manchester: Negotiable

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Senior Writer, Healthcare Advertising, London: Excellent package

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior Account Manager – Healthcare Advertising: Salary TBC

Account Manager- 4 days per week or full-time: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Training Manager - Surrey: Competitive Salary &Bonus

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Healthcare PR Senior Account Manager: Salary TBC

Senior Medical Writer: Salary is DOE

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Account Director or Senior Account Director: Salary TBC

Account Manager: Negotiable

Healthcare PR Director: £100, 000 – £120, 000 benefits

Medical Writer - Creative and Scientific Projects: DOE

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Subscribe to our email news alerts

PMHub

Add my company

Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

The gene therapy revolution: Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...